Transla'onal)Funding)Opportuni'es)) at)the)Wellcome)Trust) - PDF document

Transla'onal)Funding)Opportuni'es)) at)the)Wellcome)Trust) Innova&ons( February(2015(

Wellcome(Trust(Structure( Funding Divisions Investments Division (VC) Innovations Science Medical humanities & Society and Ethics Provides)funding)) Provides)funding)) through)programme) through)grants) related)investments) 2

Refreshed(Funding(Framework( Announced(towards(the(end(of(2014(( • Five(categories:(people,(seeds,(teams,(places(and(resources( • People:(funded(through(our(Science(division.( • • New$Inves)gator$and$Senior$Inves)gator$Award$schemes$have$ merged$$ • increased$number$of$Sir$Henry$Wellcome$Postdoctoral$ Fellowship$and$Sir$Henry$Dale$Fellowship$schemes$$ • Seeds:(funded(through(Science,(Medical(Humani&es(and(Society( and(Ethics( • Innova)ons$team$equivalent$are$the$Pathfinder$awards$

Refreshed(Funding(Framework( Teams:(Collabora&ve(awards(in(Science,(Medical(Humani&es(and( • Society(and(Ethics.( • Innova)ons$team$equivalent$are$the$PorColio$awards$ ( Places:(ongoing(support(to(Wellcome(Trust(centres(in(the(UK(and(in( • lowO(and(middleOincome(countries( ( Resources:(funding(for(shared(equipment,(facili&es(and(research( • resources,(including(support(for(longitudinal(studies.( Innova&ons(changes:((( Pathfinder(and(PorRolio(awards(

Innovations: Closing the funding gap Fund applied research and development projects to a stage where they are attractive to a follow-on funder, such as venture capital firms, industry and public-private partnerships.

Innovations Funding: 2002 to present Input) 330 projects supported 1200 Range: £25K - £11.2M 1000 £592 million committed 800 600 Output) 400 200 £1.45 billion leveraged (£363m in FY 2013/14) 0 01/2 02/3 03/4 04/5 05/6 06/7 07/8 08/9 09/10 10/11 11/12 12/13 32 exits via M&A/listing TT Funding Commitment ( £ M) or licensing 15 products launched Total Follow-on Fundraising (£ M) 29 projects in clinic

Vaccines Diagnostics 8% 11% Technology(Types(( Enabling Therapeutics Technology funded( 40% 14% Medical Devices 23% Regenerative Cardiovascular Medicine Other & Circulatory 4% 15% 10% Gastrointestinal Veterinary 1% 1% Respiratory 4% Infectious Ophthalmology Diseases 5% 31% Therapeu&c(Areas( Oncology 13% funded( ( Metabolic & Neurology Endocrinology Musculo-skeletal 11% 4% 5%

Funding schemes Health Innovation Challenge Fund Translation Fund (with Department of Health) Affordable Healthcare Seeding Drug in India Discovery Portfolio Awards Pathfinders

Translational Funding Typical)Applica'on)Process) Preliminary Application Triage (Funding Committee) Scientific & Technical Full Application Competitors Risk Analysis Expert Opinions Regulatory Milestones Due Diligence Competence IP & Legal Commercial Strategy Funding Committee (TFC, SDD, HICF JFP, SAC) Corporate Background Concept notes also required for AHI and TF

Funding(–(Points(to(Note( • The(Trust(does(not(currently(conduct(porRolio(analysis(to(priori&se( funding(areas.( However,(we(do(emphasize(being(a(‘Gap’(funder.( • • As(part(of(the(applica&on(process,(the(projects(are(assessed(in( terms(of(redundancy.(If(other(funders(or(industry(groups(are( funding(a(specific(drug(or(vaccine(target,(we(need(to(understand( clearly(how(another(approach(could(add(value.(( Programmes(are(typically(3O4(years((early(SDD(and(Pathfinder(are( • excep&ons)( Funding(in(range(of(£2O4M(( •

Delivering(value(:(Our(“rules”( • Based(on(scien&fic(excellence(and(unmet(medical(need(rather( than(commercial(objec&ve,(but( • Route(to(market(important( • Limited(exposure(to(infrastructure(costs((direct(project(costs,( no(overheads)( • Outsource(ac&vi&es(to(CROs(where(appropriate(( • Project(managed,(with(success(driven,(milestone(based( programme(related(investment( • Mul&disciplinary(teams(of(an(op&mal(size,(supported(with( experienced(advisors(

Transla&on(Fund( • Scheme(for(truly( excep'onal,)paradigm)shi?ing)projects (that(O(due( to(the(combina&on(of(poten&al(high(impact,(risk,(scale(or( complexity(O(warrant(strategic(status.(( ( • Wide(range(of(biomedical(developments(can(be(considered,( including(therapeu&cs,(vaccines,(diagnos&cs,(enabling( technologies,(medical(devices(and(regenera&ve(medicine.(( The(Trust(will(normally(ac&vely(par&cipate(in(the(stewardship(of( • the(project(and(lead(on(intellectual(property(management(and( exploita&on.((

Transla&on(Fund( ( • Invite(only,(following(considera&on(of(a(concept(note(( • PorRolios(as(well(as(single(projects(are(considered(( ( Can(support(first(in(man(studies(( • Two(commifee(mee&ngs(a(year( • ( Next(concept(note(deadline:(15(April(2015( • (

Case(study(( ( • (Shortage(of(blood(donors(plus(recipients(of(blood(transfusions(are(at(( (((risk(of(transmission(of(infec&ous(diseases(and(incompa&bility.( • (Problems(might(be(solved(using(stem(cells.( • (Free(from(infec&on,(can(be(grown(indefinitely(in(the(laboratory(and(( (((can(be(“turned(into”(many(different(cell(types,(including(red(blood(( (((cells.(( • (Professor(Marc(Turner(and(colleagues(awarded(transla&onal(funding(( (((to(op&mise(the(produc&on(of(red(blood(cells(from(stem(cells.

Case(study(

Seeding(Drug(Discovery(( £210M,(10(year(fund(launched(in(2006(to(facilitate( earlyAstage) • smallAmolecule)drug)discovery ( Aim(is(to(develop(drugOlike,(small(molecules(that(will(be(afrac&ve( • to(followOon(investors( ( Two(entry(points(to(scheme:(Early((£1(to(£2M(for(1(to(2(years)(and( • Late((~£3O4(M(for(3(to(4(years)(( ( Successful(Early(Stage(projects(can(come(back(for(Late(Stage( • funding(without(having(to(go(through(the(triage(stage( ( Two(calls(per(year,(triage(commifee(then(full(commifee.(( • Next(preliminary(applica&on(deadline:( 5)June)2015) (

Seeding(Drug(Discovery( years 3-6 month 6-12 month 12-24 month 12 month Development (years) Assay Lead Pre-clinical Target Hit to lead IND filing Development Optimisation Evaluation Discovery Early Late “To develop drug-like, small molecules that will be the springboard for further R & D by the industry in areas of unmet medical need”

Seeding(Drug(Discovery(( Trust(provides(expert(advisor(to(sit(on(research(steering(group.(( • Organiza&on(expected(to(employ(a(dedicated(project(manager.( • Research(steering(groups(are(implemented(to(keep(projects(on( • track(to(preOdefined(milestones.(( Intellectual(property(management(groups(implemented(as(a(forum( • to(discuss(IP(and(commercialisa&on(strategy.( ((

Case(Study(( ( Professor(Malcolm(Walkinshaw(at(the(University(of(Edinburgh(has( • been(awarded(funding(for(a(programme(to(target(trypanosome( phosphofructokinase(for(the(treatment(of(Human(African( Trypanosomiasis( ( £3.5M(award,(30(month(programme(through(to(iden&fica&on(of( • preOclinical(candidate.(((

Case(Study((

Translational Funding The Wellcome Trust Health(Innova&on(Challenge(Fund( Focus)on:) • (Innova&ve(healthcare(products,(technologies(and(interven&ons.( • (Unmet(healthcare(needs(in(the(NHS( • (Projects(that(are(within(three(to(five(years(of(launch(or(adop&on.(( ( Themed)calls:) • (Surgical(technologies( • (Innova&ve(diagnos&cs( • (Trauma(and(cri&cal(care(medicine( • (Informa&cs(to(assist(clinical(decision(making( • (Repurposing(of(technologies(and(medicines( • (Biological(therapies( • (Usually(two(calls(per(year(but(no(deadline(currently(published (

Case(study(( ( • (Immediate(Point(of(Care(Molecular(Diagnos&cs(for(Lung(( (((Inflamma&on/Infec&on(in(Cri&cal(Care.( • (At(least(40%(of(all(pa&ents(in(ICU(need(a(ven&lator(to(support(their(( (((lungs,(with(many(associated(complica&ons.(Once(established(on(( (((mechanical(ven&la&on,(cri&cally(ill(pa&ents(are(at(risk(of(Acute(Lung(( (((Injury((ALI)(and(secondary(infec&on(resul&ng(in(ven&lator(associated(( (((pneumonia((VAP).( • (Professor(Chris(Haslef(and(colleagues(at(the(University(of(Edinburgh(( (((are(developing(smart(probes(to(detect(the(presence(of(neutrophilic(( (((infiltra&on(or(the(presence(of(bacteria(at(sites(of(lung(injury.

Affordable(Healthcare(in(India( To(fund(transla&onal(research(projects(that(will(deliver(safe(and( • effec&ve(healthcare(products(for(India(O(and(poten&ally(other( markets(O(at(affordable(costs.( ( Encourages(innova&ons(that(bring(together(researchers(from(both( • the(public(and(private(sectors(to(extend(access(to(care(to(the( greatest(numbers(of(beneficiaries,(without(compromising(on( quality.(( ( • Principal(Inves&gator(must(be(based(in(India(but(can(have(overseas( collaborators(